ELAC2 and prostate cancer: Approximately 6% of the Caucasian population possess the Ala541Thr variant (Vesprini et al, 2001), and genetic and genome‐wide association studies (GWAS) have predicted that this variant can increase the risk of prostate cancer (Tavtigian et al, 2001); however, functional and physiological validation for the effects of ELAC2 variants on prostate cancer and enzyme function is lacking.